SAN DIEGO, April 10, 2018 /PRNewswire/ -- Imprimis
Pharmaceuticals, Inc. (NASDAQ: IMMY), and its ophthalmology-focused
ImprimisRx division, today announced its participation and related
physician presentations at the 2018 American Society of Cataract
and Refractive Surgery (ASCRS) Annual Meeting to be held at the
Walter E. Washington Convention Center in Washington, DC, April
13-17. The company will join the largest U.S. meeting
that integrates a scientific program dedicated to the needs of
anterior segment specialists, practice management staff, and
ophthalmic technicians and nurses.
At the conference, attendees will have the opportunity to meet
with Imprimis representatives in Booth #2218 to learn about
Imprimis' proprietary formulations and its recently launched Custom
Compound Program. This new program provides high-quality compounded
medications that are often difficult to find and typically needed
quickly.
Imprimis formulations will be featured in the following sessions
during ASCRS:
- Clinical Outcomes after Use of New Combinations of Topical
Antiocular Hypertensive Medications to Maintain or Lower IOP in
Patients with Glaucoma – Inder Paul
Singh, MD
-
- Dropless® Cataract Surgery:
Alternative Advanced Drug-Delivery Method for Cataract Surgery
Patients – Abdullah Nasser, MD,
Barry Emara, MD
-
- Session: SPS – 308 Medications
- Monday, April 16 – 2:28 PM-2:33 PM
- Level 1, 143B
Additional formulations and ordering information will be
available at Booth #2218 in the exhibit hall at the Walter E.
Washington Convention Center.
ABOUT IMPRIMIS PHARMACEUTICALS
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is dedicated to
making high-quality innovative medications accessible and
affordable in all 50 states. The company's flexible business
model allows a drug to be compounded or developed as an
FDA-approved product through one of its subsidiaries or spin-out
companies. For more information about Imprimis, please visit
the corporate website at www.ImprimisRx.com.
SAFE HARBOR
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
CONTACTS
Media Contact:
Deb Holliday
Holliday Communications, Inc.
deb@hollidaycommunications.net
412-877-4519
Investor Contact:
Jon Patton
jpatton@imprimispharma.com
858-704-4587
View original content with
multimedia:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-to-feature-its-patent-pending-cyclosporinechondroitin-sulfate-and-patented-non-opioid-mko-melt-midazolamketamineondansetron-formulations-at-the-upcoming-cataract--refractive-surgery-medical-meeting-300626616.html
SOURCE Imprimis Pharmaceuticals, Inc.